UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Second-line Chemotherapy with Biweekly Paclitaxel after Failure of Fluoropyrimidine-based Treatment in Patients with Advanced or Recurrent Gastric Cancer: a Report from the Gastrointestinal Oncology Group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 Trial

Japanese journal of clinical oncology, 2009-11, Vol.39 (11), p.713-719

2009

Volltextzugriff (PDF)

Intoxication with Over-the-Counter Antitussive Medication Containing Dihydrocodeine and Chlorpheniramine Causes Generalized Convulsion and Mixed Acidosis

Internal Medicine, 2008, Vol.47(11), pp.1013-1015

2008

Volltextzugriff (PDF)

Analysis of Inhaled Corticosteroid Selection in Patients with Bronchial Asthma Using a Questionnaire Survey—Effects of Age, Gender, and Disease Severity

Allergology international, 2009, Vol.58 (3), p.365-371

2009

Volltextzugriff (PDF)

Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan

Journal of pharmaceutical health care and sciences, 2016-11, Vol.2 (1), p.30-30, Article 30

2016

Volltextzugriff (PDF)

Argatroban as a substitute for heparin during VAIVT for a patient with heparin-induced thrombocytopenia

Nihon Tōseki Igakkai Zasshi, 2018, Vol.51 (7), p.459-462

2018

Volltextzugriff (PDF)

PS4-3 Survival analysis of m-FOLFOXIRI plus cetuximab vs. bevacizumab in RAS wild-type mCRC: The DEEPER trial (JACCRO CC-13)

Annals of oncology, 2023-11, Vol.34, p.S1381-S1381

2023

Volltextzugriff (PDF)

Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.120-120

2023

Volltextzugriff (PDF)

O7-2 FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13)

Annals of oncology, 2022-07, Vol.33, p.S471

2022

Volltextzugriff (PDF)

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

European journal of cancer (1990), 2014-05, Vol.50 (8), p.1437-1445

2014

Volltextzugriff (PDF)

Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: The subgroup-analysis of DEEPER trial (JACCRO CC-13)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.109-109

2022

Volltextzugriff (PDF)

Huge Mucinous Cystic Neoplasm of the Pancreas in a Young Diabetic Woman

Internal Medicine, 2008, Vol.47(23), pp.2097-2097

2008

Volltextzugriff (PDF)

The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3501-3501

2021

Volltextzugriff (PDF)

Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.86-86

2021

Volltextzugriff (PDF)

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

Oncotarget, 2018-04, Vol.9 (27), p.18811-18820

2018

Volltextzugriff (PDF)

Interim safety analysis of a phase II trial of modified-FOXFOXIRI plus bevacizumab for RAS mutant mCRC (JACCRO CC-11)

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix91

2017

Volltextzugriff (PDF)

A pooled analysis of the secondary resection for colorectal cancer liver metastases: Comparison of bevacizumab (Bmab) and anti-EGFRs

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.610-610

2016

Volltextzugriff (PDF)

MO1-16-1Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_6)

2019

Volltextzugriff (PDF)

Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer

Annals of oncology, 2019-10, Vol.30, p.vi96

2019

Volltextzugriff (PDF)

Analysis of Inhaled Corticosteroid Selection in Patients with Bronchial Asthma Using a Questionnaire Survey -Effects of Age, Gender, and Disease Severity

Allergology International, 2009, Vol.58 (3), p.365-371

2009

Volltextzugriff (PDF)

The risk of adverse events of CPT- 11

Nihon rinshō, 2016-11, Vol.74 (11), p.1847

2016

Volltextzugriff (PDF)

Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes

Diabetes (New York, N.Y.), 1996-04, Vol.45 (4), p.488-495

1996

Volltextzugriff (PDF)

18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)

Oncology and therapy, 2021-12, Vol.9 (2), p.635-645

2021

Volltextzugriff (PDF)

Regulation of survival and death of mesangial cells by extracellular matrix

Kidney international, 1998-10, Vol.54 (4), p.1188-1196

1998

Volltextzugriff (PDF)

Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker for the efficacy: JACCRO CC-11

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.635-635

2018

Volltextzugriff (PDF)

1 – 25 von 292

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(216)
Mit Volltextzugriff
(238)

Publikationsform

Sprache

Englisch
(260)
Japanisch
(38)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial

Second-line Chemotherapy with Biweekly Paclitaxel after Failure of Fluoropyrimidine-based Treatment in Patients with Advanced or Recurrent Gastric Cancer: a Report from the Gastrointestinal Oncology Group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 Trial

Intoxication with Over-the-Counter Antitussive Medication Containing Dihydrocodeine and Chlorpheniramine Causes Generalized Convulsion and Mixed Acidosis

Analysis of Inhaled Corticosteroid Selection in Patients with Bronchial Asthma Using a Questionnaire Survey—Effects of Age, Gender, and Disease Severity

Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan

Argatroban as a substitute for heparin during VAIVT for a patient with heparin-induced thrombocytopenia

PS4-3 Survival analysis of m-FOLFOXIRI plus cetuximab vs. bevacizumab in RAS wild-type mCRC: The DEEPER trial (JACCRO CC-13)

Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO

O7-2 FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13)

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: The subgroup-analysis of DEEPER trial (JACCRO CC-13)

Huge Mucinous Cystic Neoplasm of the Pancreas in a Young Diabetic Woman

The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13)

Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13)

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

Interim safety analysis of a phase II trial of modified-FOXFOXIRI plus bevacizumab for RAS mutant mCRC (JACCRO CC-11)

A pooled analysis of the secondary resection for colorectal cancer liver metastases: Comparison of bevacizumab (Bmab) and anti-EGFRs

MO1-16-1Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer

Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer

Analysis of Inhaled Corticosteroid Selection in Patients with Bronchial Asthma Using a Questionnaire Survey -Effects of Age, Gender, and Disease Severity

The risk of adverse events of CPT- 11

Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes

18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)

Regulation of survival and death of mesangial cells by extracellular matrix

Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker for the efficacy: JACCRO CC-11

Suchergebnisse filtern